Displaying drugs 14126 - 14150 of 14185 in total
Pevonedistat
Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.
Investigational
Matched Iupac: … [(1S,2S,4R)-4-(4-{[(1S)-2,3-dihydro-1H-inden-1-yl]amino}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
MK-1454
A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB)...
Investigational
Matched Description: … (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3 ... binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 ... A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), …
Iclaprim
Investigational
Matched Iupac: … 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Quaternium-18
Quaternium-18 is a mixture of quaternary ammonium chloride salts. Quaternium-18 Hectorite and Bentonite are the reaction products of Quaternium-18 with clays. These compounds are poorly absorbed through the skin. Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.
Experimental
Matched Description: … Quaternium-18 is a mixture of quaternary ammonium chloride salts. …
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
Urelumab
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in...
Investigational
Matched Description: … Urelumab is a fully human antibody that targets CD137. ... studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell …
CoVac-1
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein . It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults...
Investigational
Matched Name: … CoVac-1 …
Matched Description: … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine …
Matched Description: … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine …
Olmutinib
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
Matched Iupac: … N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide …
Matched Description: … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Reglitazar
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Investigational
Matched Iupac: … 4-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)-1,2-oxazolidine-3,5-dione …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
SYNB1353
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion...
Investigational
Matched Description: … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered …
Dilmapimod
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been...
Investigational
Matched Iupac: … 8-(2,6-difluorophenyl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-methylphenyl)-7H,8H-pyrido[2,3 …
Matched Description: … Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions …
Matched Salts cas: … 937169-00-1 …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions …
Matched Salts cas: … 937169-00-1 …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
ROX-888
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
Matched Description: … ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain …
Tucidinostat
Investigational
Matched Iupac: … N-(2-amino-4-fluorophenyl)-4-{[(2E)-3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Talmapimod
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Investigational
Matched Iupac: … -3-yl}-N,N-dimethyl-2-oxoacetamide ... 2-{6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methyl-1H-indol …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Tariquidar
Investigational
Matched Iupac: … N-[2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbamoyl)-4,5-dimethoxyphenyl ... ]quinoline-3-carboxamide …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
4-O-Demethylpenclomedine
Investigational
Matched Iupac: … 3,5-dichloro-2-methoxy-6-(trichloromethyl)-1,4-dihydropyridin-4-one …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
MEM 1414
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Matched Description: … This drug candidate has completed Phase 1 clinical trials. ... MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. …
Firocoxib
Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use...
Experimental
Vet approved
Matched Iupac: … 3-(cyclopropylmethoxy)-4-(4-methanesulfonylphenyl)-5,5-dimethyl-2,5-dihydrofuran-2-one …
Matched Description: … Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. ... Firocoxib was the first COX-2 inhibitor approved by the U.S. …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Selective Cyclooxygenase 2 Inhibitors (NSAIDs) …
Matched Description: … Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. ... Firocoxib was the first COX-2 inhibitor approved by the U.S. …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Selective Cyclooxygenase 2 Inhibitors (NSAIDs) …
Deracoxib
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Iupac: … 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide …
Matched Description: … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Cnidium monnieri fruit
Experimental
Gepotidacin
Gepotidacin has been used in trials studying the treatment of Gonorrhea, Infections, Bacterial, and Infections, Respiratory Tract.
Investigational
Matched Iupac: … (3R)-3-({4-[({2H,3H,4H-pyrano[2,3-c]pyridin-6-yl}methyl)amino]piperidin-1-yl}methyl)-1,4,7-triazatricyclo …
Matched Salts cas: … 1624306-20-2 …
Matched Salts cas: … 1624306-20-2 …
Remikiren
Remikiren is an orally active, high specificity renin inhibitor.
Experimental
Matched Iupac: … (2S)-2-[(2S)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl ... -3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Zenarestat
Experimental
Matched Iupac: … 2-{3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl}acetic acid …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Mirfentanil
Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor. At lower doses, it antagonizes the analgesic effects of alfentanil and substitutes for naloxone in morphine-treated monkeys; however, it also reverses naloxone-precipitated withdrawal in pigeons trained to discriminate morphine from naloxone. At high doses, it...
Experimental
Matched Iupac: … N-[1-(2-phenylethyl)piperidin-4-yl]-N-(pyrazin-2-yl)furan-2-carboxamide …
Matched Description: … Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Displaying drugs 14126 - 14150 of 14185 in total